- Home
- LCTX vs ME Comparison
LCTX vs ME Comparison
Compare LCTX & ME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- ME
- Stock Information
- Founded
- LCTX 1990
- ME 2006
- Country
- LCTX United States
- ME United States
- Employees
- LCTX N/A
- ME N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- ME Precision Instruments
- Sector
- LCTX Health Care
- ME Health Care
- Exchange
- LCTX Nasdaq
- ME Nasdaq
- Market Cap
- LCTX 165.6M
- ME 168.9M
- IPO Year
- LCTX N/A
- ME N/A
- Fundamental
- Price
- LCTX $0.89
- ME $0.30
- Analyst Decision
- LCTX Strong Buy
- ME Hold
- Analyst Count
- LCTX 3
- ME 1
- Target Price
- LCTX $5.67
- ME $0.47
- AVG Volume (30 Days)
- LCTX 432.3K
- ME 2.6M
- Earning Date
- LCTX 08-08-2024
- ME 11-06-2024
- Dividend Yield
- LCTX N/A
- ME N/A
- EPS Growth
- LCTX N/A
- ME N/A
- EPS
- LCTX N/A
- ME N/A
- Revenue
- LCTX $6,186,000.00
- ME $199,188,000.00
- Revenue This Year
- LCTX N/A
- ME $0.05
- Revenue Next Year
- LCTX $119.00
- ME $17.98
- P/E Ratio
- LCTX N/A
- ME N/A
- Revenue Growth
- LCTX N/A
- ME N/A
- 52 Week Low
- LCTX $0.77
- ME $0.30
- 52 Week High
- LCTX $1.61
- ME $1.16
- Technical
- Relative Strength Index (RSI)
- LCTX 48.84
- ME 34.11
- Support Level
- LCTX $0.83
- ME $0.30
- Resistance Level
- LCTX $0.94
- ME $0.32
- Average True Range (ATR)
- LCTX 0.06
- ME 0.02
- MACD
- LCTX 0.00
- ME 0.00
- Stochastic Oscillator
- LCTX 46.23
- ME 0.00
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.